The LIGHT-COG Study (NCT07083154) is a Phase 3 clinical trial investigating the efficacy, safety, and tolerability of a GLP-1/GCG (Glucagon) Dual Receptor Agonist in patients with Type 2 Diabetes and early dementia, particularly Alzheimer's disease[1].
This trial represents a novel therapeutic approach targeting the metabolic dysfunction hypothesis of neurodegeneration, leveraging the neuroprotective effects of GLP-1 receptor agonism. It is one of the first large-scale Phase 3 trials to directly test whether metabolic modulation can slow cognitive decline in AD patients with diabetes.
| Field | Value |
|---|---|
| NCT Number | NCT07083154 |
| Status | Recruiting |
| Phase | Phase 3 |
| Enrollment | 420 participants (estimated) |
| Study Type | Interventional |
| Allocation | Randomized, parallel-group |
| Intervention Model | Double-blind, placebo-controlled |
| Start Date | September 27, 2025 |
| Completion Date | August 1, 2029 |
| Primary Outcome | Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change[2] |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Arm | Intervention | Dose | Duration |
|---|---|---|---|
| Active | GLP-1/GCG Dual Agonist | TBD | 52 weeks |
| Placebo | Matching placebo | N/A | 52 weeks |
| Endpoint | Measure | Timepoint |
|---|---|---|
| Cognition | MMSE | Baseline, Week 26, Week 52 |
| Cognition | ADAS-Cog13 | Baseline, Week 52 |
| Function | ADCS-ADL | Baseline, Week 52 |
| Global | CDR-SB | Baseline, Week 52 |
| Brain imaging | Hippocampal volume (MRI) | Baseline, Week 52 |
| Biomarkers | CSF Aβ40, Aβ42, total tau, p-tau181 | Baseline, Week 52 |
| Biomarkers | Plasma Aβ, p-tau, NfL | Baseline, Week 26, Week 52 |
Epidemiological studies have established a strong link between Type 2 Diabetes and increased risk of Alzheimer's disease. The metabolic dysfunction in diabetes contributes to[3]:
Impaired glucose metabolism in the brain
Increased neuroinflammation
Oxidative stress
Blood-brain barrier dysfunction
Emerging evidence supports the concept of Alzheimer's disease as a form of diabetes[3:1]:
GLP-1 receptor agonists, originally developed for diabetes treatment, have shown neuroprotective properties in preclinical models[4]:
| Mechanism | Effect |
|---|---|
| Insulin sensitization | Enhances brain insulin sensitivity |
| Anti-inflammatory | Reduces microglial activation |
| Anti-apoptotic | Prevents neuronal death |
| Synaptic protection | Preserves synaptic function |
| Aβ reduction | Decreases amyloid plaque formation |
| Tau modulation | Reduces tau phosphorylation |
| Autophagy enhancement | Improves protein clearance |
| Mitochondrial function | Preserves neuronal energy metabolism |
The dual GLP-1/GCG agonist may provide enhanced neuroprotection:
The dual mechanism addresses both peripheral and central metabolic dysfunction, which are increasingly recognized as key contributors to Alzheimer's disease pathogenesis[5].
| Institution | City | Province |
|---|---|---|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University | Nanjing | Jiangsu |
| Nanjing First Hospital, Nanjing Medical University | Nanjing | Jiangsu |
| Shanghai General Hospital, Shanghai Jiao Tong University | Shanghai | Shanghai |
| Xiangya Hospital of Central South University | Changsha | Hunan |
| Huadong Hospital | Nanjing | Jiangsu |
| Jiangsu Province Hospital of Traditional Chinese Medicine | Nanjing | Jiangsu |
| Changzhou No.2 People's Hospital | Changzhou | Jiangsu |
| The Second Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |
| Biomarker | Sample | Expected Change |
|---|---|---|
| HbA1c | Blood | Reduced |
| Fasting glucose | Blood | Reduced |
| GLP-1 levels | Plasma | Increased |
| Biomarker | Sample | Purpose |
|---|---|---|
| Aβ40/Aβ42 | CSF | Amyloid burden |
| Total tau | CSF | Neurodegeneration |
| p-tau181 | CSF | Tau pathology |
| NfL | Plasma | Axonal injury |
| Neurogranin | CSF | Synaptic dysfunction |
| Drug | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| LIGHT-COG | Nanjing Drum Tower | Phase 3 | Recruiting | GLP-1/GCG dual |
| Semaglutide | Novo Nordisk | Phase 3 | Completed | GLP-1 |
| Liraglutide | Novo Nordisk | Phase 2 | Completed | GLP-1 |
| Exenatide | AstraZeneca | Phase 2 | Completed | GLP-1 |
| Dapagliflozin | BMS | Phase 2 | Recruiting | SGLT2 |
| Approach | Target | Development Stage |
|---|---|---|
| GLP-1/GIP dual | GLP-1/GIP receptors | Phase 2-3 |
| GLP-1/GCG dual | GLP-1/GCC receptors | Phase 3 |
| SGLT2 inhibitors | Glucose reabsorption | Phase 2 |
| Insulin sensitizers | PPARγ | Phase 2 |
| Metabolic modulators | mTOR, AMPK | Preclinical |
| Event | Frequency | Management |
|---|---|---|
| Nausea | Common (20-30%) | Gradual titration, anti-emetics |
| Vomiting | Less common (5-10%) | Dose adjustment |
| Diarrhea | Common (10-15%) | Supportive care |
| Hypoglycemia | Rare (2-3%) | Monitor, adjust diabetes meds |
| Pancreatitis | Rare (<1%) | Immediate discontinuation |
The LIGHT-COG trial is actively recruiting as of March 2026. Enrollment is expected to complete by mid-2027, with topline results in 2029.
Milestones:
This trial is significant because:
Diabetes and Alzheimer's disease: shared genetic and cellular mechanisms. Alzheimer's & Dementia. 2021. ↩︎
Integrated Alzheimer's Disease Rating Scale (iADRS). Journal of Prevention of Alzheimer's Disease. 2017. ↩︎
Type 3 diabetes: a link between Alzheimer's disease and diabetes. CNS Drugs. 2021. ↩︎ ↩︎
GLP-1 receptor agonists for neuroprotection in Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎
Metabolic dysfunction in Alzheimer's disease. Nature Reviews Disease Primers. 2022. ↩︎